Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics, Inc. (DSGN)
Company Research
Source: GlobeNewswire
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inception through its strategic $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW grew into a fully integrated global biotech organization and successfully commercialized Epidiolex® (cannabidiol), which is approved in the U.S. and Europe for the treatment of childhood onset epilepsies. As part of this transition, Dr. Arsani William, Managing Partner and Chief Investment Officer of Logos Capital, stepped down from the Board, effective Se
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.MarketBeat
- Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Design Therapeutics (NASDAQ:DSGN) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.MarketBeat
- Design Therapeutics (NASDAQ:DSGN) was given a new $14.00 price target on by analysts at Leerink Partners.MarketBeat
- Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
DSGN
Earnings
- 11/5/25 - Beat
DSGN
Sec Filings
- 11/18/25 - Form SCHEDULE
- 11/18/25 - Form 144
- 11/14/25 - Form 144
- DSGN's page on the SEC website